原发性胆汁性胆管炎肝内小胆管上皮细胞损伤的免疫学机制

杨雅斐; 邓志华

doi:10.3969/j.issn.1001-5256.2021.06.051

原发性胆汁性胆管炎肝内小胆管上皮细胞损伤的免疫学机制

DOI: 10.3969/j.issn.1001-5256.2021.06.051

杨雅斐,
邓志华^,

山西医科大学第二医院消化内科，太原 030001

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：杨雅斐负责课题设计，查阅文献，撰写文章；邓志华负责指导、修改文章。

详细信息

作者简介:
杨雅斐(1993—)，女，主要从肝病方面研究

通信作者:
邓志华，ykdzh@Hotmail.com

中图分类号: R575.7
计量
- 文章访问数: 508
- HTML全文浏览量: 165
- PDF下载量: 72
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-16
- 录用日期: 2020-12-10
- 出版日期: 2021-06-20

Immune mechanism of biliary epithelial cell injury in the small intrahepatic bile ducts in primary biliary cholangitis

Yafei YANG,
Zhihua DENG^,

Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种遗传和环境因素共同作用的、以肝内小胆管上皮细胞(BEC)凋亡性坏死为特征的慢性自身免疫性肝病。阐述了PBC时B淋巴细胞、巨噬、自然杀伤(NK)、NKT和T淋巴细胞等对BEC的免疫损伤作用，为PBC免疫靶向治疗提供一定的指导意义。
- 原发性胆汁性胆管炎 /
- 胆管上皮细胞 /
- 细胞免疫 /
- 细胞因子类
Abstract: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease caused by the combined effect of genetic and environmental factors and characterized by the apoptotic necrosis of biliary epithelial cells (BEC) in the small intrahepatic bile ducts. This article describes the effect of B cells, macrophages, natural killer cells, NKT, and T cells on the immune injury of BEC during PBC, so as to provide some guidance for the targeted immune therapy for PBC.
- rimary Biliary Cholangitis /
- Biliary Epithelial Cells /
- Cell-Mediated Immunity /
- Cytokines

HTML全文

图 1 免疫系统对BEC的作用

下载: 全尺寸图片幻灯片

参考文献(28)

[1]	LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
[2]	DOHERTY DG. Antigen-specific immune tolerance in the liver[J]. Nat Biomed Eng, 2019, 3(10): 763-765. DOI: 10.1038/s41551-019-0445-9.
[3]	GRANT CR, LIBERAL R. Liver immunology: How to reconcile tolerance with autoimmunity[J]. Clin Res Hepatol Gastroenterol, 2017, 41(1): 6-16. DOI: 10.1016/j.clinre.2016.06.003.
[4]	TANAKA A, LEUNG P, GERSHWIN ME. The genetics of primary biliary cholangitis[J]. Curr Opin Gastroenterol, 2019, 35(2): 93-98. DOI: 10.1097/MOG.0000000000000507.
[5]	TSUNEYAMA K, BABA H, MORIMOTO Y, et al. Primary biliary cholangitis: Its pathological characteristics and immunopathological mechanisms[J]. J Med Invest, 2017, 64(1.2): 7-13. DOI: 10.2152/jmi.64.7.
[6]	LLEO A, LEUNG P, HIRSCHFIELD GM, et al. The pathogenesis of primary biliary cholangitis: A comprehensive review[J]. Semin Liver Dis, 2020, 40(1): 34-48. DOI: 10.1055/s-0039-1697617.
[7]	ARSENIJEVIC A, STOJANOVIC B, MILOVANOVIC J, et al. Galectin-3 in inflammasome activation and primary biliary cholangitis development[J]. Int J Mol Sci, 2020, 21(14). DOI: 10.3390/ijms21145097.
[8]	RONCA V, MANCUSO C, MILANI C, et al. Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis[J]. J Leukoc Biol, 2020, 108(2): 659-671. DOI: 10.1002/JLB.5MR0320-200R.
[9]	GIORDANO DM, PINTO C, MARONI L, et al. Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies[J]. Int J Mol Sci, 2018, 19(10): 3003. DOI: 10.3390/ijms19103003.
[10]	TANAKA A, LEUNG P, GERSHWIN ME. Evolution of our understanding of PBC[J]. Best Pract Res Clin Gastroenterol, 2018, 34-35: 3-9. DOI: 10.1016/j.bpg.2018.05.008.
[11]	TAYLOR SA, ASSIS DN, MACK CL. The contribution of B cells in autoimmune liver diseases[J]. Semin Liver Dis, 2019, 39(4): 422-431. DOI: 10.1055/s-0039-1688751.
[12]	CHUNG BK, GUEVEL BT, REYNOLDS GM, et al. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis[J]. J Autoimmun, 2017, 77: 45-54. DOI: 10.1016/j.jaut.2016.10.003.
[13]	MA WT, CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci (Lond), 2019, 133(6): 741-760. DOI: 10.1042/CS20181123.
[14]	FU HY, BAO WM, YANG CX, et al. Kupffer cells regulate natural killer cells via the NK group 2, member D (NKG2D)/retinoic acid early inducible-1 (RAE-1) interaction and cytokines in a primary biliary cholangitis mouse model[J]. Med Sci Monit, 2020, 26: e923726. DOI: 10.12659/MSM.923726.
[15]	HYDES TJ, BLUNT MD, NAFTEL J, et al. Constitutive activation of natural killer cells in primary biliary cholangitis[J]. Front Immunol, 2019, 10: 2633. DOI: 10.3389/fimmu.2019.02633.
[16]	LI Y, LI B, YOU Z, et al. Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis[J]. J Autoimmun, 2019, 103: 102293. DOI: 10.1016/j.jaut.2019.06.004.
[17]	BERNTSEN NL, FOSBY B, TAN C, et al. Natural killer T cells mediate inflammation in the bile ducts[J]. Mucosal Immunol, 2018, 11(6): 1582-1590. DOI: 10.1038/s41385-018-0066-8.
[18]	ZHAO SX, LI WC, FU N, et al. Emperipolesis mediated by CD8(+) T cells correlates with biliary epithelia cell injury in primary biliary cholangitis[J]. J Cell Mol Med, 2020, 24(2): 1268-1275. DOI: 10.1111/jcmm.14752.
[19]	CHEN Q, LAI L, CHI X, et al. CD19(+)CD24(hi)CD38(hi) B cell dysfunction in primary biliary cholangitis[J]. Mediators Inflamm, 2020, 2020: 3019378. DOI: 10.1155/2020/3019378.
[20]	GREEN DS, YOUNG HA, VALENCIA JC. Current prospects of type Ⅱ interferon γ signaling and autoimmunity[J]. J Biol Chem, 2017, 292(34): 13925-13933. DOI: 10.1074/jbc.R116.774745.
[21]	YANG C, MAI H, PENG J, et al. STAT4: An immunoregulator contributing to diverse human diseases[J]. Int J Biol Sci, 2020, 16(9): 1575-1585. DOI: 10.7150/ijbs.41852.
[22]	TANAKA A, LEUNG P, YOUNG HA, et al. Therapeutic and immunological interventions in primary biliary cholangitis: From mouse models to humans[J]. Arch Med Sci, 2018, 14(4): 930-940. DOI: 10.5114/aoms.2017.70995.
[23]	CAPONE A, VOLPE E. Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases[J]. Front Immunol, 2020, 11: 348. DOI: 10.3389/fimmu.2020.00348.
[24]	DRESCHER HK, BARTSCH LM, WEISKIRCHEN S, et al. Intrahepatic TH17/TReg cells in homeostasis and disease-it's all about the balance[J]. Front Pharmacol, 2020, 11: 588436. DOI: 10.3389/fphar.2020.588436.
[25]	SUN Q, WANG Q, FENG N, et al. The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis[J]. Ann Transl Med, 2019, 7(16): 389. DOI: 10.21037/atm.2019.07.100.
[26]	CHEN J, HOU X, JIA H, et al. Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis[J]. Oncotarget, 2017, 8(65): 108406-108417. DOI: 10.18632/oncotarget.22658.
[27]	LIASKOU E, PATEL SR, WEBB G, et al. Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells[J]. J Autoimmun, 2018, 94: 143-155. DOI: 10.1016/j.jaut.2018.07.020.
[28]	ZHANG Q, LU W, LIANG CL, et al. Chimeric antigen receptor (CAR) Treg: A promising approach to inducing immunological tolerance[J]. Front Immunol, 2018, 9: 2359. DOI: 10.3389/fimmu.2018.02359.